Expanding the DNA alphabet: ‘extra’ DNA base found to be stable

A rare DNA base, previously thought to be a temporary modification, has been shown to be stable in mammalian DNA, suggesting that it plays a key role in cellular function.
Researchers from the University of Cambridge and the Babraham Institute have found that a naturally occurring modified DNA base appears to be stably incorporated in the DNA of many mammalian tissues, possibly representing an expansion of the functional DNA alphabet.
The new study, published today in the journal Nature Chemical Biology, has found that this rare ‘extra’ base, known as 5-formylcytosine (5fC) is stable in living mouse tissues. While its exact function is yet to be determined, 5fC’s physical position in the genome makes it likely that it plays a key role in gene activity.
“If 5fC is present in the DNA of all tissues, it is probably there for a reason,” said Professor Shankar Balasubramanian of the Department of Chemistry and the Cancer Research UK Cambridge Institute, who led the research. “It had been thought this modification was solely a short-lived intermediate, but the fact that we’ve demonstrated it can be stable in living tissue shows that it could regulate gene expression and potentially signal other events in cells.”
Related News
See all news-
Future scientists join our second Cambridge LaunchPad project day
18th August 2025
Students from Thomas Clarkson Academy in Wisbech joined us for a unique opportunity to experience the world of cancer research first-hand.
Find out more -
Single-cell study sheds new light on why ovarian cancer becomes resistant to chemotherapy
11th August 2025
Researchers at the Cancer Research UK Cambridge Institute and Stanford University have mapped how ovarian cancer cells respond to chemotherapy at an unprecedented level of detail, offering new insights into why treatment resistance develops.
Find out more -
New clue discovered for why some cancer drugs fall short
11th July 2025
Hedgehog signalling plays a key role in controlling how immune cells migrate into tumours, a discovery that may explain why some cancer drugs have underperformed in clinical trials.
Read more